altHIGHLIGHTS

  • No new countries reported cases of COVID-19 in the past 24 hours.
  • WHO has developed a database to collect the latest scientific findings and knowledge on Coronavirus disease. For more information, please see here.
  • The two-day global research and innovation forum regarding COVID-19 was convened in line with the WHO R&D Blueprint this week. Leading health experts from around the world met at WHO to assess the current level of knowledge about the new COVID-19 disease, identify gaps and work together to accelerate and fund priority research needed to help stop this outbreak and prepare for any future outbreaks. For more details, please see here.

China

Very High

Regional Level

High

Global Level

High

Overnight 14’840 cases, including 13’332 clinically diagnosed cases were reported from Hubei. This is the first time China has reported clinically diagnosed cases in addition to laboratory-confirmed cases. For consistency, we report here only the number of laboratory-confirmed cases. WHO has formally requested additional information on the clinically diagnosed cases, in particular when these have occurred in the course of the outbreak and whether suspect cases were reclassified as clinically diagnosed cases.

SITUATION IN NUMBERS

total and new cases in last 24 hours

Globally 46 997 confirmed (1826new)

China46 550 confirmed (1820 new)1368 deaths (254 new)

Outside of China447 confirmed (6 new)24 countries1 death WHO RISK ASSESSMENT

ChinaVery High

Regional Level High

Global Level High

TECHNICAL FOCUS: Investigation of COVID-19 cases outside of China

As of 10am CET 13 Feb 2020, a total of 170 cases of COVID-19 who had a travel history to China have been reported outside of China. The vast majority of these (151, 89%) do not appear to lead to further transmission of the virus, while the remaining 19 have been associated with onward transmission within 12 distinct groups of epidemiologically linked cases (Fig 2). Among these, four groups have involved at least nine individuals. The largest involves 20 individuals in six countries thus far - United Kingdom (6), France (5), Malaysia (3), Singapore (3), Republic of Korea (2), Spain (1) - and has been linked to a conference held in Singapore between 20 and 22 January 2020 and a subsequent ski trip to the French Alps (Table 1, Figure 2). The next largest involves 15 cases and was linked to a conference in Bavaria, Germany. Among the attendees was an individual with an epidemiological link to confirmed cases in Wuhan, China. Additionally, one of the 15 cases was detected in, but did not involve transmission within, Spain.

Sixteen cases have been reported in four countries for which there are no clearly established epidemiological links. For all these individuals, investigations are ongoing to establish the mechanism by which they were infected.

STRATEGIC OBJECTIVES

WHO’s strategic objectives for this response are to:

  • Limit human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events, and preventing further international spread from China*;
  • Identify, isolate and care for patients early, including providing optimized care for infected patients;
  • Identify and reduce transmission from the animal source;
  • Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment options, and accelerate the development of diagnostics, therapeutics and vaccines;
  • Communicate critical risk and event information to all communities and counter misinformation;
  • Minimize social and economic impact through multisectoral partnerships.

*This can be achieved through a combination of public health measures, such as rapid identification, diagnosis and management of the cases, identification and follow up of the contacts, infection prevention and control in health care settings, implementation of health measures for travelers, awareness-raising in the population and risk communication.

PREPAREDNESS AND RESPONSE

countermeasures such as case isolation, contact tracing and isolation. Several protocols are available here: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations

  • WHO is working with its networks of researchers and other experts to coordinate global work on surveillance, epidemiology, modelling, diagnostics, clinical care and treatment, and other ways to identify, manage the disease and limit onward transmission. WHO has issued interim guidance for countries, which are updated regularly.
  • WHO is working with global expert networks and partnerships for laboratory, infection prevention and control, clinical management and mathematical modelling.

RECOMMENDATIONS AND ADVICE FOR THE PUBLIC

During previous outbreaks due to other coronavirus (Middle-East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), human-to-human transmission occurred through droplets, contact and fomites, suggesting that the transmission mode of the COVID-19 can be similar. The basic principles to reduce the general risk of transmission of acute respiratory infections include the following:

  • Avoiding close contact with people suffering from acute respiratory infections.
  • Frequent hand-washing, especially after direct contact with ill people or their environment.
  • Avoiding unprotected contact with farm or wild animals.
    • People with symptoms of acute respiratory infection should practice cough etiquette (maintain distance, cover coughs and sneezes with disposable tissues or clothing, and wash hands).
    • Within health care facilities, enhance standard infection prevention and control practices in hospitals, especially in emergency departments.

WHO does not recommend any specific health measures for travellers. In case of symptoms suggestive of respiratory illness either during or after travel, travellers are encouraged to seek medical attention and share their travel history with their health care provider.


OBJECTIVES

 

WHO’s strategic objectives for this response are to:

 

·Â Â Â Â Â Â Â Â  Limit human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events, and preventing further international spread from China*;

·Â Â Â Â Â Â Â Â  Identify, isolate and care for patients early, including providing optimized care for infected patients;

·Â Â Â Â Â Â Â Â  Identify and reduce transmission from the animal source;

·Â Â Â Â Â Â Â Â  Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment options, and accelerate the development of diagnostics, therapeutics and vaccines;

·Â Â Â Â Â Â Â Â  Communicate critical risk and event information to all communities and counter misinformation;

·Â Â Â Â Â Â Â Â  Minimize social and economic impact through multisectoral partnerships.

 

*This can be achieved through a combination of public health measures, such as rapid identification, diagnosis and management of the cases, identification and follow up of the contacts, infection prevention and control in health care settings, implementation of health measures for travelers, awareness-raising in the population and risk communication Normal 0 21 false false false FR X-NONE X-NONE

Ajouter un Commentaire


Code de sécurité
Rafraîchir

Vitrines Sociétés

Voir toutes les vitrines